Cantor Fitzgerald’s DexCom DXCM Stock Holding History

Cantor Fitzgerald’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-161,000	Closed	-$15M	–	342
2023 Q3	$15M	Hold	161,000	–	–	0.4%	89
2023 Q2	$20.7M	Buy	+161,000	New	+$19.5M	0.47%	71

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cantor Fitzgerald's DXCM Position: Q4 2023 in Review

Cantor Fitzgerald sold out of DexCom (DXCM) in Q4 2023, closing a stake of 161,000 shares — an estimated $15M sold.

Cantor Fitzgerald first reported a position in DXCM in Q2 2023 and held it in 2 quarters. The position peaked at $20.7M in Q2 2023. 974 funds tracked by Wall St. Rank hold DXCM as of Q4 2023.

Cantor Fitzgerald reported no remaining DexCom position as of Q4 2023 after selling out during the quarter.
Cantor Fitzgerald sold 161,000 DexCom shares in Q4 2023, an estimated $15M.
Cantor Fitzgerald first reported a position in DexCom in Q2 2023 and held it in 2 quarters.
Cantor Fitzgerald's DexCom position peaked at $20.7M in Q2 2023.
974 funds tracked by Wall St. Rank held DexCom as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.